Bibliographies thématiques / Proteina TDP43

Littérature scientifique sur le sujet « Proteina TDP43 »

Auteur : Grafiati
Publié le 11 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Proteina TDP43 ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Proteina TDP43"

1

Hill, Sarah J., Daniel A. Mordes, Lisa A. Cameron, Donna S. Neuberg, Serena Landini, Kevin Eggan et David M. Livingston. « Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage ». Proceedings of the National Academy of Sciences 113, no 48 (14 novembre 2016) : E7701—E7709. http://dx.doi.org/10.1073/pnas.1611673113.

Texte intégral
Résumé :
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron dysfunction disease that leads to paralysis and death. There is currently no established molecular pathogenesis pathway. Multiple proteins involved in RNA processing are linked to ALS, including FUS and TDP43, and we propose a disease mechanism in which loss of function of at least one of these proteins leads to an accumulation of transcription-associated DNA damage contributing to motor neuron cell death and progressive neurological symptoms. In support of this hypothesis, we find that FUS or TDP43 depletion leads to increased sensitivity to a transcription-arresting agent due to increased DNA damage. Thus, these proteins normally contribute to the prevention or repair of transcription-associated DNA damage. In addition, both FUS and TDP43 colocalize with active RNA polymerase II at sites of DNA damage along with the DNA damage repair protein, BRCA1, and FUS and TDP43 participate in the prevention or repair of R loop-associated DNA damage, a manifestation of aberrant transcription and/or RNA processing. Gaining a better understanding of the role(s) that FUS and TDP43 play in transcription-associated DNA damage could shed light on the mechanisms underlying ALS pathogenesis.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Luo, Jiayi, et Paul M. Harrison. « Evolution of sequence traits of prion-like proteins linked to amyotrophic lateral sclerosis (ALS) ». PeerJ 10 (17 novembre 2022) : e14417. http://dx.doi.org/10.7717/peerj.14417.

Texte intégral
Résumé :
Prions are proteinaceous particles that can propagate an alternative conformation to further copies of the same protein. They have been described in mammals, fungi, bacteria and archaea. Furthermore, across diverse organisms from bacteria to eukaryotes, prion-like proteins that have similar sequence characters are evident. Such prion-like proteins have been linked to pathomechanisms of amyotrophic lateral sclerosis (ALS) in humans, in particular TDP43, FUS, TAF15, EWSR1 and hnRNPA2. Because of the desire to study human disease-linked proteins in model organisms, and to gain insights into the functionally important parts of these proteins and how they have changed across hundreds of millions of years of evolution, we analyzed how the sequence traits of these five proteins have evolved across eukaryotes, including plants and metazoa. We discover that the RNA-binding domain architecture of these proteins is deeply conserved since their emergence. Prion-like regions are also deeply and widely conserved since the origination of the protein families for FUS, TAF15 and EWSR1, and since the last common ancestor of metazoa for TDP43 and hnRNPA2. Prion-like composition is uncommon or weak in any plant orthologs observed, however in TDP43 many plant proteins have equivalent regions rich in other amino acids (namely glycine and tyrosine and/or serine) that may be linked to stress granule recruitment. Deeply conserved low-complexity domains are identified that likely have functional significance.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Laudanski, Krzysztof, Jihane Hajj, Mariana Restrepo, Kumal Siddiq, Tony Okeke et Daniel J. Rader. « Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes ». Biomedicines 9, no 12 (29 novembre 2021) : 1791. http://dx.doi.org/10.3390/biomedicines9121791.

Texte intégral
Résumé :
The balance between neurodegeneration, neuroinflammation, neuroprotection, and COVID-19-directed therapy may underly the heterogeneity of SARS-CoV-2′s neurological outcomes. A total of 105 patients hospitalized with a diagnosis of COVID-19 had serum collected over a 6 month period to assess neuroinflammatory (MIF, CCL23, MCP-1), neuro-injury (NFL, NCAM-1), neurodegenerative (KLK6, τ, phospho τ, amyloids, TDP43, YKL40), and neuroprotective (clusterin, fetuin, TREM-2) proteins. These were compared to markers of nonspecific inflammatory responses (IL-6, D-dimer, CRP) and of the overall viral burden (spike protein). Data regarding treatment (steroids, convalescent plasma, remdasavir), pre-existing conditions, and incidences of strokes were collected. Amyloid β42, TDP43, NF-L, and KLK6 serum levels declined 2–3 days post-admission, yet recovered to admission baseline levels by 7 days. YKL-40 and NCAM-1 levels remained elevated over time, with clusters of differential responses identified among TREM-2, TDP43, and YKL40. Fetuin was elevated after the onset of COVID-19 while TREM-2 initially declined before significantly increasing over time. MIF serum level was increased 3–7 days after admission. Ferritin correlated with TDP-43 and KLK6. No treatment with remdesivir coincided with elevations in Amyloid-β40. A lack of convalescent plasma resulted in increased NCAM-1 and total tau, and steroidal treatments did not significantly affect any markers. A total of 11 incidences of stroke were registered up to six months after initial admission for COVID-19. Elevated D-dimer, platelet counts, IL-6, and leukopenia were observed. Variable MIF serum levels differentiated patients with CVA from those who did not have a stroke during the acute phase of COVID-19. This study demonstrated concomitant and opposite changes in neurodegenerative and neuroprotective markers persisting well into recovery.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Carter, G. Campbell, Chia-Heng Hsiung, Leman Simpson, Haopeng Yang et Xin Zhang. « N-terminal Domain of TDP43 Enhances Liquid-Liquid Phase Separation of Globular Proteins ». Journal of Molecular Biology 433, no 10 (mai 2021) : 166948. http://dx.doi.org/10.1016/j.jmb.2021.166948.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Raghunathan, Rekha, Kathleen Turajane et Li Chin Wong. « Biomarkers in Neurodegenerative Diseases : Proteomics Spotlight on ALS and Parkinson’s Disease ». International Journal of Molecular Sciences 23, no 16 (18 août 2022) : 9299. http://dx.doi.org/10.3390/ijms23169299.

Texte intégral
Résumé :
Neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) are both characterized by pathogenic protein aggregates that correlate with the progressive degeneration of neurons and the loss of behavioral functions. Both diseases lack biomarkers for diagnosis and treatment efficacy. Proteomics is an unbiased quantitative tool capable of the high throughput quantitation of thousands of proteins from minimal sample volumes. We review recent proteomic studies in human tissues, plasma, cerebrospinal fluid (CSF), and exosomes in ALS and PD that identify proteins with potential utility as biomarkers. Further, we review disease-related post-translational modifications in key proteins TDP43 in ALS and α-synuclein in PD studies, which may serve as biomarkers. We compare relative and absolute quantitative proteomic approaches in key biomarker studies in ALS and PD and discuss recent technological advancements which may identify suitable biomarkers for the early-diagnosis treatment efficacy of these diseases.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Tanaka, Hikari, et Hitoshi Okazawa. « PQBP1 : The Key to Intellectual Disability, Neurodegenerative Diseases, and Innate Immunity ». International Journal of Molecular Sciences 23, no 11 (2 juin 2022) : 6227. http://dx.doi.org/10.3390/ijms23116227.

Texte intégral
Résumé :
The idea that a common pathology underlies various neurodegenerative diseases and dementias has attracted considerable attention in the basic and medical sciences. Polyglutamine binding protein-1 (PQBP1) was identified in 1998 after a molecule was predicted to bind to polyglutamine tract amino acid sequences, which are associated with a family of neurodegenerative disorders called polyglutamine diseases. Hereditary gene mutations of PQBP1 cause intellectual disability, whereas acquired loss of function of PQBP1 contributes to dementia pathology. PQBP1 functions in innate immune cells as an intracellular receptor that recognizes pathogens and neurodegenerative proteins. It is an intrinsically disordered protein that generates intracellular foci, similar to other neurodegenerative disease proteins such as TDP43, FUS, and hnRNPs. The knowledge accumulated over more than 20 years has given rise to a new concept that shifts in the equilibrium between physiological and pathological processes have their basis in the dysregulation of common protein structure-linked molecular mechanisms.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Lee, Yichen, Bo H. Lee, William Yip, Pingchen Chou et Bak-Sau Yip. « Neurofilament Proteins as Prognostic Biomarkers in Neurological Disorders ». Current Pharmaceutical Design 25, no 43 (9 janvier 2020) : 4560–69. http://dx.doi.org/10.2174/1381612825666191210154535.

Texte intégral
Résumé :
Neurofilaments: light, medium, and heavy (abbreviated as NF-L, NF-M, and NF-H, respectively), which belong to Type IV intermediate filament family (IF), are neuron-specific cytoskeletal components. Neurofilaments are axonal structural components and integral components of synapses, which are important for neuronal electric signal transmissions along the axons and post-translational modification. Abnormal assembly of neurofilaments is found in several human neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), infantile spinal muscular atrophy (SMA), and hereditary sensory-motor neuropathy (HSMN). In addition, those pathological neurofilament accumulations are known in α-synuclein in Parkinson’s disease (PD), Aβ and tau in Alzheimer’s disease (AD), polyglutamine in CAG trinucleotide repeat disorders, superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TDP43), neuronal FUS proteins, optineurin (OPTN), ubiquilin 2 (UBQLN2), and dipeptide repeat protein (DRP) in amyotrophic lateral sclerosis (ALS). When axon damage occurs in central nervous disorders, neurofilament proteins are released and delivered into cerebrospinal fluid (CSF), which are then circulated into blood. New quantitative analyses and assay techniques are well-developed for the detection of neurofilament proteins, particularly NF-L and the phosphorylated NF-H (pNF-H) in CSF and serum. This review discusses the potential of using peripheral blood NF quantities and evaluating the severity of damage in the nervous system. Intermediate filaments could be promising biomarkers for evaluating disease progression in different nervous system disorders.
Styles APA, Harvard, Vancouver, ISO, etc.
8

Jiang, Tianlin, Jiahua Wang, Chao Li, Guiyun Cao et Xiaohong Wang. « Prohibitins : A Key Link between Mitochondria and Nervous System Diseases ». Oxidative Medicine and Cellular Longevity 2022 (8 juillet 2022) : 1–13. http://dx.doi.org/10.1155/2022/7494863.

Texte intégral
Résumé :
Prohibitins (PHBs) are conserved proteins in eukaryotic cells, which are mainly located in the inner mitochondrial membrane (IMM), cell nucleus, and cell membrane. PHBs play crucial roles in various cellular functions, including the cell cycle regulation, tumor suppression, immunoglobulin M receptor binding, and aging. In addition, recent in vitro and in vivo studies have revealed that PHBs are important in nervous system diseases. PHBs can prevent apoptosis, inflammation, mitochondrial dysfunction, and autophagy in neurological disorders through different molecules and pathways, such as OPA-1, PINK1/Parkin, IL6/STAT3, Tau, NO, LC3, and TDP43. Therefore, PHBs show great promise in the protection of neurological disorders. This review summarizes the relevant studies on the relationship between PHBs and neurological disorders and provides an update on the molecular mechanisms of PHBs in nervous system diseases.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Tang, Fu-Lei, Lu Zhao, Yang Zhao, Dong Sun, Xiao-Juan Zhu, Lin Mei et Wen-Cheng Xiong. « Coupling of terminal differentiation deficit with neurodegenerative pathology in Vps35-deficient pyramidal neurons ». Cell Death & ; Differentiation 27, no 7 (6 janvier 2020) : 2099–116. http://dx.doi.org/10.1038/s41418-019-0487-2.

Texte intégral
Résumé :
AbstractVps35 (vacuolar protein sorting 35) is a key component of retromer that regulates transmembrane protein trafficking. Dysfunctional Vps35 is a risk factor for neurodegenerative diseases, including Parkinson’s and Alzheimer’s diseases. Vps35 is highly expressed in developing pyramidal neurons, and its physiological role in developing neurons remains to be explored. Here, we provide evidence that Vps35 in embryonic neurons is necessary for axonal and dendritic terminal differentiation. Loss of Vps35 in embryonic neurons results in not only terminal differentiation deficits, but also neurodegenerative pathology, such as cortical brain atrophy and reactive glial responses. The atrophy of neocortex appears to be in association with increases in neuronal death, autophagosome proteins (LC3-II and P62), and neurodegeneration associated proteins (TDP43 and ubiquitin-conjugated proteins). Further studies reveal an increase of retromer cargo protein, sortilin1 (Sort1), in lysosomes of Vps35-KO neurons, and lysosomal dysfunction. Suppression of Sort1 diminishes Vps35-KO-induced dendritic defects. Expression of lysosomal Sort1 recapitulates Vps35-KO-induced phenotypes. Together, these results demonstrate embryonic neuronal Vps35’s function in terminal axonal and dendritic differentiation, reveal an association of terminal differentiation deficit with neurodegenerative pathology, and uncover an important lysosomal contribution to both events.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Miguelez-Rodriguez, Aitzol, Jorge Santos-Juanes, Ikerne Vicente-Etxenausia, Katty Perez de Heredia-Goñi, Beatriz Garcia, Luis M. Quiros, Laura Lorente-Gea, Isabel Guerra-Merino, Jose J. Aguirre et Ivan Fernandez-Vega. « Brains with sporadic Creutzfeldt-Jakob disease and copathology showed a prolonged end-stage of disease ». Journal of Clinical Pathology 71, no 5 (2 novembre 2017) : 446–50. http://dx.doi.org/10.1136/jclinpath-2017-204794.

Texte intégral
Résumé :
AimsTo investigate the expression of major proteins related to primary neurodegenerative diseases and their prognostic significance in brains with Creutzfeldt-Jakob disease (CJD).Materials and methodsThirty consecutive cases of confirmed CJD during the period 2010–2015 at Basque Brain bank were retrospectively reviewed. Moreover, major neurodegenerative-associated proteins (phosphorylated Tau, 4R tau, 3R tau, alpha-synuclein, TDP43, amyloid beta) were tested. Clinical data were reviewed. Cases were divided according to the presence or absence of copathology. Survival curves were also determined.ResultsCopathology was significantly associated with survival in brains with CJD (4.2±1.2 vs 9.2±1.9; P=0.019) and in brains with MM1/MV1 CJD (2.1±1.0 vs 6.7±2.8; P=0.012). Besides, the presence of more than one major neurodegenerative-associated protein was significantly associated with survival (4.2±1.2 vs 10.7±2.6; P=0.017). Thus, univariate analyses further pointed out variables significantly associated with better survival: copathology in CJD (HR=0.430; P=0.033); more than one neurodegenerative-associated protein in CJD (HR=0.369; P=0.036) and copathology in MM1/MV1 CJD (HR=0.525; P=0.032).ConclusionThe existence of copathology significantly prolongs survival in patients with rapidly progressive dementia due to CJD. The study of major neurodegenerative-associated proteins in brains with CJD could allow us to further understand the molecular mechanisms behind prion diseases.
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Proteina TDP43"

1

Fourier, Anthony. « Vers un marqueur biochimique des dégénérescences lobaires fronto-temporales : variations quantitatives et profils protéiques de la protéine TDP43 dans différentes matrices biologiques ». Thesis, Lyon, 2018. http://www.theses.fr/2018LYSE1269/document.

Texte intégral
Résumé :
Les dégénérescences lobaires frontotemporales (DLFT) représentent la deuxième étiologie neurodégénérative chez l’adulte de moins de 65 ans. Les DLFT sont constituées d’un ensemble hétérogène de phénotypes cliniques et sont fréquemment héréditaires. Leurs particularités neuropathologiques communes reposent sur une atrophie des lobes frontaux et/ou temporaux associée à la présence d’inclusions de protéines agrégées parmi lesquelles la protéine TAR DNA binding protein 43 (TDP43). Actuellement, aucun marqueur protéique n’est validé pour diagnostiquer les DLFT du vivant du patient.Une cohorte de cas certains DLFT-TDP43 a été constituée grâce au développement d’outils spécifiques de diagnostic moléculaire. Une analyse des concentrations pondérales de protéine TDP43 dans le liquide cérébrospinal (LCS) a été réalisée dans cette cohorte, puis comparée à des cohortes bien caractérisées sur le plan clinique et neuropathologique. Finalement, les profils qualitatifs de la protéine TDP43 ont été étudiés dans différents compartiments accessibles du vivant du patient : les profils des formes solubles (LCS et plasma) et des formes intracellulaires (éléments figurés du sang) de la protéine TDP43 ont été comparés aux profils protéiques obtenus sur des tissus cérébraux présentant des inclusions de protéine TDP43. Les profils protéiques des culots plaquettaires présentent des similitudes avec le tissu cérébral et pourraient devenir un marqueur candidat pour le diagnostic probabiliste des DLFT
Frontotemporal lobar degeneration (FTLD) syndrome is the second most common of presenile dementia. FTLD is a clinically heterogeneous syndrome and comprises many hereditary cases. Common neuropathological features rely on a degeneration of the frontal and/or anterior temporal lobes, associated to specific inclusions of aggregated proteins including TAR DNA binding protein 43 (TDP43). Unfortunately, no practical protein marker is currently validated to improve FTLD diagnosis in living patients.A cohort of FTLD patients with definite TDP43 pathology was defined with the development of specific genetic testing. An analysis of TDP43 concentrations in cerebrospinal fluid (CSF) was performed in this cohort and then compared to other cohorts well-characterized on clinical and neuropathological features. Finally, qualitative patterns of TDP43 were studied in compartments accessible from the patient’s living: profiles of soluble TDP43 protein (in CSF or in plasma) and intracellular TDP43 protein (in the formed elements of blood) were compared to protein patterns observed in brain tissues with TDP43 protein inclusions. Platelet samples exhibit similar characteristics to brain tissue and could become a candidate biomarker for FTLD probabilistic diagnosis
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Proteina TDP43"

1

« TARDP (TDP43, Transcription of RNA activating protein/TAR DNA binding protein, human chromosome 1p36.2) ». Dans Encyclopedia of Genetics, Genomics, Proteomics and Informatics, 1930. Dordrecht : Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6754-9_16677.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Proteina TDP43"

1

Kim, Patrick Y., Owen Tan, Toby Trahair, Tao Liu, Glenn M. Marshall et Belamy B. Cheung. « Abstract 1403 : TRIM16 inhibits cell growth through direct interaction and modulation of TDP43 protein stability in cancer cells ». Dans Proceedings : AACR Annual Meeting 2014 ; April 5-9, 2014 ; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1403.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Proteina TDP43 » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie